Barclays Maintains Equal-Weight Rating on Gilead Sciences, Raises Target to $160
Barclays maintained its Equal-Weight rating on Gilead Sciences and raised its price target to $160 per share from $145.
Barclays maintained its Equal-Weight rating on Gilead Sciences and raised its price target to $160 per share from $145.